MIRM
No price yet
Announcements
Nothing here yet
Daily updates
- Mirum Pharmaceuticals reported positive Phase 3 EXPAND results for LIVMARLI (maralixibat) in ultra-rare cholestatic liver diseases, showing significant reductions in pediatric pruritus versus placebo and a 69% decrease in serum bile acids.Oct 12, 2026
- Mirum reported Phase 3 AZURE-1 results for brelovitug in chronic hepatitis D, positioning the program as a potential competitor to Gilead’s Hepcludex.Sep 30, 2026
- Mirum Pharmaceuticals reported positive Phase 3 AZURE-1 results for brelovitug in chronic hepatitis delta, with the Week 24 primary endpoint achieved by 56% of patients receiving 300 mg weekly and 45% receiving 900 mg monthly versus 0% in the delayed-treatment cohort.Sep 28, 2026
FDA designations
Nothing here yet
News
- Mirum Pharmaceuticals reports that brelovitug met the primary endpoint in the Phase 3 AZURE-1 study for chronic hepatitis delta virus infectionSep 28, 2026
- Mirum Pharmaceuticals and Incyte receive U.S. FDA approval for Atebrioz (zilurgisertib) in adults and children with fibrodysplasia ossificans progressivaSep 26, 2026
- Mirum and Incyte reported positive pivotal Phase 2 PROGRESS study results for zilurgisertib in fibrodysplasia ossificans progressivaJun 15, 2026
- Mirum Pharmaceuticals reported achieving the primary endpoint in the VISTAS study of VolixibatMay 4, 2026
- Mirum Pharmaceuticals met the primary endpoint in the Phase 2b portion of the AZURE-1 study of Brelovitug in chronic hepatitis delta virusApr 27, 2026